Advanced search
Publication Cover
Expert Opinion on Emerging Drugs Volume 10, 2005 - Issue 1
Submit an article Journal homepage
73
Views
6
CrossRef citations to date
0
Altmetric
Review

Emerging analgesics in cancer pain management

Lukas Radbruch University of Aachen, Department of Palliative Medicine, Pauwelsstrasse 30, 52074 Aachen, Germany. [email protected]
&
Frank Elsner University of Aachen, Department of Palliative Medicine, Pauwelsstrasse 30, 52074 Aachen, Germany. [email protected]
Pages 151-171 | Published online: 22 Apr 2005

Bibliography

  • BONICA JJ: Cancer Pain. In Management of Pain. Bonica JJ (ed.) Lea 8c Febiger, Philadelphia (1990): 400–460.
  • ZECH DF, GROND S, LYNCH J, HERTEL D, LEHMANN KA: Validation of World Health Organization Guidelines for cancer pain relief: a 10-year prospective study. Pain (1995) 63: 65–76.
  • CARACENI A, PORTENOY RK, ASHBY MA et al.: An international survey of cancer pain characteristics and syndromes. Pain (1999) 82(3):263–274.
  • COYLE N: In their own words: seven advanced cancer patients describe their experience with pain and the use of opioid drugs. J. Pain Symptom Manage. (2004) 27(4):300–309.
  • KUSNECOV AW, RABIN BS: Stressor-induced alterations of immune function: mechanisms and issues. Int. Arch. Allergy Immunol. (1994) 105(2):107–121.
  • WORLD HEALTH ORGANIZATION: Cancer pain relief with a guide to opioid availability. WHO (ed.) WHO, Geneva, (1996).
  • DE STOUTZ ND, BRUERA E, SUAREZ-ALMAZOR M: Opioid rotation for toxicity reduction in terminal cancer patients. J. Pain Symptom Manage. (1995) 10(5):378–384.
  • HAWLEY P, FORBES K, HANKS GW: Opioids, confusion and opioid rotation. Palliat. Med. (1998) 12:63–64.
  • MERCADANTE S, RADBRUCH L, CARACENI A et al.: Episodic (breakthrough) pain: consensus conference of an expert working group of the European Association for Palliative Care. Cancer (2002) 94(3):832–839.
  • GROND S, ZECH D, DIEFENBACH C, BISCHOFF A: Prevalence and pattern of symptoms in patients with cancer pain: a prospective evaluation of 1635 cancer patients referred to a pain clinic. J. Pain Symptom Manage. (1994) 9: 372–382.
  • JADAD AR, BROWMAN GP: The WHO analgesic ladder for cancer pain management. Stepping up the quality of its evaluation. JAMA (1995) 274(23):1870–1873.
  • BRUNSCH-RADBRUCH A, RADBRUCH L, STEDEN E et al.: Transdermales fentanyl in der klinischen Praxis - eine Anwendungsbeobachtung. Schmerz (1997) 11 (Supp1.1):S53.
  • BOGER RH, SCHMIDT G: Analgetika. In Arneiverordnungsreport 2001. Schwabe U et al. (eds) Springer, Berlin (2001):89–102.
  • SCHMIDT G: Analgetika. In Arzneiverordnungsreport 1991. Schwabe U et al. (eds) Gustav Fischer Verlag, Stuttgart (19911:20–31.
  • NAUCK F, OSTGATHE C, KLASCHIK E et al.: Drugs in palliative care: results from a representative survey in Germany. Palliat. Med. (2004) 18(2):100–107.
  • LEHMANN KA, RADBRUCH L, GOCKEL HH, NEIGHBORS D, NUYTS G: Costs of opioid therapy for chronic nonmalignant pain in Germany: an economic model comparing transdermal fentanyl (Durogesic) with controlled-release morphine. Eur. j Healh. Econom. (2002) 3:111–119.
  • HANKS G, PORTENOY RK, MACDONALD N, FORBES K: Difficult pain problems. In Word Textbook ofPalliat. Med. Doyle D et al. (eds) Oxford Medical Publications, Oxford (1998):454–477.
  • MANTYH PW, CLOHISY DR, KOLTZENBURG M, HUNT SP: Molecular mechanisms of cancer pain. Nat. Rev Cancer (2002) 2(3):201–209.
  • HONORE P, SCHWEI J, ROGERS SD et al.: Cellular and neurochemical remodeling of the spinal cord in bone cancer pain. Prog-. Brain Res. (2000) 129:389–397.
  • REGAN JM, PENG P: Neurophysiology ofcancer pain. Cancer Control (2000) 7(2):111–119.
  • AHMAD SR, KORTEPETER C, BRINKER A, CHEN M, BEITZ J: Renal failure associated with the use of celecoxib and rofecoxib. Drug Saf (2002) 25(7):537–544.
  • WARNER TD, MITCHELL JA: Cyclooxygenases: new forms, new inhibitors, and lessons from the clinic. Faseb. J. (2004) 18(7):790–804.
  • HARVEY RJ, DEPNER UB, WASSLE H et al.: GlyR alpha3: an essential target for spinal PGE2-mediated inflammatory pain sensitization. Science (2004) 304(5672):884–887.
  • KISMET K, AKAY MT, ABBASOGLU O, ERCAN A: Celecoxib: a potent cyclooxygenase-2 inhibitor in cancer prevention. Cancer Detect. Prey. (2004) 28(2):127–142.
  • DAVIS TW, ZWEIFEL BS, O'NEAL JM et al.: Inhibition of cyclooxygenase-2 by celecoxib reverses tumor-induced wasting. PharmacoL Exp. Ther. (2004) 308(3):929–934.
  • WOLFE F, ZHAO S, PETTITT D: Blood pressure destabilization and edema among 8538 users of celecoxib, rofecoxib, and nonselective nonsteroidal antiinflammatory drugs (NSAID) and nonusers of NSAID receiving ordinary clinical care. RheumatoL (2004) 31(6):1143–1151.
  • RAY WA, STEIN CM, DAUGHERTY JR et al.: COX-2 selective non-steroidal anti-inflammatory drugs and risk of serious coronary heart disease. Lancet (2002) 360(9339):1071–1073.
  • WHELTON A, WHITE WB, BELLO AE, PUMA JA, FORT JG: Effects of celecoxib and rofecoxib on blood pressure and edema in patients > or =65 years of age with systemic hypertension and osteoarthritis. Am. J. CardioL (2002) 90(9):959–963.
  • MAMDANI M, JUURLINK DN, LEE DS et al.: Cyclo-oxygenase-2 inhibitors versus non-selective non-steroidal anti-inflammatory drugs and congestive heart failure outcomes in elderly patients: a population-based cohort study. Lancet (2004) 363(9423):1751–1756.
  • BALLANTYNE JC, MAO J: Opioid therapy for chronic pain. N EngL J. Med. (2003) 349(20):1943–1953.
  • HANKS GW, DECONNO F, CHERNY N et al.: Morphine and alternative opioids in cancer pain: the EAPC recommendations. Br. J. Cancer (2001) 84:587–593.
  • TEGEDER I, GEISSLINGER G: Einsatz von Opioiden bei Leber- oder Niereninsuffizienz. Schmerz (1999) 13: 183–195.
  • LIKAR R, GRIESSINGER N, SADJAK A, SITTL R: Transdermal buprenorphine for treatment of chronic tumour and non-tumour pain. Wien. Med. Wochenschr. (2003) 153(13-14):317–322.
  • BOHME K, BLOMS-FUNKE P, GILLEN C, SCHUETTLER AJ, WNENDT S: Buprenorphine in a transdermal therapeutic system-a new option. Agonistic effects of the opioid buprenorphine on the nociceptin/OFQ receptor. Clin. RheumatoL (2002) 21\(Suppl. 1)(7):S13–516.
  • GOBEL H, STADLER T: [Treatment of post-herpes zoster pain with tramadol. Results of an open pilot study versus clomipramine with or without levomepromazine]. Drugs (1997) 53\(Suppl. 2):34–39.
  • DELLEMIJN PL, VANNESTE JA: Randomised double-blind active-placebo-controlled crossover trial of intravenous fentanyl in neuropathic pain. Lancet (1997) 347:753–758.
  • MEGENS AA, ARTOIS K, VERMEIRE J, MEERT T, AWOUTERS FH: Comparison of the analgesic and intestinal effects of fentanyl and morphine in rats. J. Pain Symptom Manage. (1998) 15(4):253–258.
  • AHMEDZAI S, BROOKS D: Transdermal fentanyl versus sustained-release oral morphine in cancer pain: preference, efficacy, and quality of life. The TTS-Fentanyl Comparative Trial Group. J. Pain Symptom Manage. (1997) 13: 254–261.
  • ALLAN L, HAYS H, JENSEN NH et al.: Randomised crossover trial of transdermal fentanyl and sustained release oral morphine for treating chronic non-cancer pain. BMJ (2001) 322(7295):1154.
  • MUCCI-LORUSSO P, BERMAN BS, SILBERSTEIN PT et al.: Controlled-release oxycodone compared with controlled-release morphine in the treatment of cancer pain: a randomized, double-blind, parallel-group study. Eur. J. Pain (1998) 2(2):239–249.
  • MADDOCKS I, SOMOGYI A, ABBOTT F, HAYBALL P, PARKER D: Attenuation of morphine-induced delirium in palliative care by substitution with infusion of oxycodone. J. Pain Symptom Manage. (1996) 12(3):182–189.
  • HIROTA T, IEIRI I, TAKANE H et al: Sequence variability and candidate gene analysis in two cancer patients with complex clinical outcomes during morphine therapy. Drug Metab. Dispos. (2003) 31(5):677–680.
  • ROSS FB, SMITH MT: The intrinsic antinociceptive effects of oxycodone appear to be kappa-opioid receptor mediated. Pain (1997) 73(2):151–157.
  • YOBURN BC, SHAH S, CHAN K, DUTTAROY A, DAVIS T: Supersensitivity to opioid analgesics following chronic opioid antagonist treatment: relationship to receptor selectivity. PharmacoL Biochem. Behav. (1995) 51(2-3):535–539.
  • NIELSEN CK, ROSS FB, SMITH MT: Incomplete, asymmetric, and route-dependent cross-tolerance between oxycodone and morphine in the Dark Agouti rat. J. Pharmacol. Exp. Ther. (2000) 295(1):91–99.
  • GORMAN AL, ELLIOTT KJ, INTURRISI CE: The d- and 1-isomers of methadone bind to the non-competitive site on the N-methyl-D-aspartate (NMDA) receptor in rat forebrain and spinal cord. Neurosci. Lett. (1997) 223(1):5–8.
  • SHIMOYAMA N, SHIMOYAMA M, ELLIOTT KJ, INTURRISI CE: D-Methadone is antinociceptive in the rat formalin test. J. PharmacoL Exp. Ther. (1997) 283(2):648–652.
  • CARPENTER KJ, CHAPMAN V, DICKENSON AH: Neuronal inhibitory effects of methadone are predominantly opioid receptor mediated in the rat spinal cord in vivo. Eur. J. Pain (2000) 4(1):19–26.
  • RADY JJ, HOLMES BB, PORTOGHESE PS, FUJIMOTO JM: Morphine tolerance in mice changes response of heroin from mu to delta opioid receptors. Proc. Soc. Exp. Biol. Med. (2000) 224(2):93–101.
  • CICHEWICZ DL, MARTIN ZL, SMITH FL, WELCH SP: Enhancement mu opioid antinociception by oral delta9-tetrahydrocannabinol: dose-response analysis and receptor identification. PharmacoL Exp. Ther. (1999) 289(2):859–867.
  • WILLERT RP, WOOLF CJ, HOBSON AR, et al.: The development and maintenance of human visceral pain hypersensitivity is dependent on the N-methyl-D-aspartate receptor. Gastroenterology (2004) 126(3):683–692.
  • BURSZTAJN S, RUTKOWSKI MD, DELEO JA: The role of the N-methyl-D-aspartate receptor NR1 subunit in peripheral nerve injury-induced mechanical allodynia, glial activation and chemokine expression in the mouse. Neuroscience (2004) 125(1):269–275.
  • MERCADANTE S, LODI F, SAPIO M, CALLIGARA M, SERRETTA R: Long-term ketamine subcutaneous continuous infusion in neuropathic cancer pain. J. Pain Symptom Manage. (1995) 10(7):564–568.
  • KANNAN TR, SAXENA A, BHATNAGAR S, BARRY A: Oral ketamine as an adjuvant to oral morphine for neuropathic pain in cancer patients. J. Pain Symptom Manage. (2002) 23(1):60–65.
  • MERCADANTE S, ARCURI E, TIRELLI W, CASUCCIO A: Analgesic effect of intravenous ketamine in cancer patients on morphine therapy: a randomized, controlled, double-blind, crossover, double-dose study. J. Pain Symptom Manage. (2000) 20(4):246–252.
  • BROADLEY KE, KUROWSKA A, TOOKMAN A: Ketamine injection used orally. Palliat. Med. (1996) 10(3):247–250.
  • LAURETTI GR, LIMA IC, REIS MP, PRADO WA, PEREIRA NL: Oral ketamine and transdermal nitroglycerin as analgesic adjuvants to oral morphine therapy for cancer pain management. Anesthesiology (1999) 90(6):1528–1533.
  • PUD D, EISENBERG E, SPITZER A et al: The NMDA receptor antagonist amantadine reduces surgical neuropathic pain in cancer patients: a double blind, randomized, placebo controlled trial. Pain (1998) 75(2-3):349–354.
  • Memantine in the treatment of diabetics with painful peripheral neuropathy: a placebo-controlled phase IIb trial. Pain Med (2002) 3(2):182.
  • EISENBERG E, KLEISER A, DORTORT A, HAIM T, YARNITSKY D: The NMDA (N-methyl-D-aspartate) receptor antagonist memantine in the treatment of postherpetic neuralgia: a double-blind, placebo-controlled study. Eur. J. Pain (1998) 2(4):321–327.
  • MATER C, DERTWINKEL R, MANSOURIAN N et al: Efficacy of the NMDA-receptor antagonist memantine in patients with chronic phantom limb pain-results of a randomized double-blinded, placebo-controlled trial. Pain (2003) 103(3):277–283.
  • NIKOLAJSEN L, GOTTRUP H, KRISTENSEN AG, JENSEN TS: Memantine (a N-methyl-D-aspartate receptor antagonist) in the treatment of neuropathic pain after amputation or surgery: a randomized, double-blinded, cross-over study. Anesth. Analg. (2000) 91(4):960–966.
  • WIECH K, KIEFER RT, TOPFNER S et al: A placebo-controlled randomized crossover trial of the N-methyl-D-aspartic acid receptor antagonist, memantine, in patients with chronic phantom limb pain. Anesth. Analg. (2004) 98(2):408–413, table of contents.
  • MERCADANTE S, CASUCCIO A, GENOVESE G: Ineffectiveness of dextromethorphan in cancer pain. J. Pain Symptom Manage. (1998) 16(5):317–322.
  • KATZ NP: MorphiDex (MS:DM) double-blind, multiple-dose studies in chronic pain patients. J. Pain Symptom Manage. (2000) 19\(Suppl. 1):S37–S41.
  • BEN ABRAHAM R, MAROUANI N, WEINBROUM AA: Dextromethorphan mitigates phantom pain in cancer amputees. Ann. Surg. OncoL (2003) 10(3):268–274.
  • WEINBROUM AA, BENDER B, BICKELS J et al: Preoperative and postoperative dextromethorphan provides sustained reduction in postoperative pain and patient-controlled epidural analgesia requirement: a randomized, placebo-controlled, double-blind study in lower-body bone malignancy-operated patients. Cancer (2003) 97(9):2334–2340.
  • EBERT B, THORKILDSEN C, ANDERSEN S, CHRISTRUP LL, HJEDS H: Opioid analgesics as noncompetitive N-methyl-D-aspartate (NMDA) antagonists. Biochem. PharmacoL (1998) 56(5):553–559.
  • MAKIN MK, ELLERSHAW JE: Substitution of another opioid for morphine. Methadone can be used to manage neuropathic pain related to cancer. BMJ (1998) 317(7150):81.
  • BRAGA MF, ARONIADOU-ANDERJASKA V, POST RM, LT H: Lamotrigine reduces spontaneous and evoked GABAA receptor-mediated synaptic transmission in the basolateral amygdala: implications for its effects in seizure and affective disorders. Neuropharmacology (2002) 42(4):522–529.
  • ASHTON H, YOUNG AH: GABA-ergic drugs: exit stage left, enter stage right. PsychopharmacoL (2003) 17(2):174–178.
  • LAUGHLIN TM, TRAM KV, WILCOX GL, BIRNBAUM AK: Comparison of antiepileptic drugs tiagabine, lamotrigine, and gabapentin in mouse models of acute, prolonged, and chronic nociception. PharmacoL Exp. Ther. (2002) 302(3):1168–1175.
  • JASMIN L, TIEN D, JANNI G, OHARA PT: Is noradrenaline a significant factor in the analgesic effect of antidepressants? Pain (2003) 106(1-2):3–8.
  • CANAVERO S, BONICALZI V: Norepinephrine and pain. Pain (2004) 107(3):279.
  • LYNCH ME: Antidepressants as analgesics: a review of randomized controlled trials. J. Psychiatry Neurosci. (2001) 26(1):30–36.
  • DURAND JP, GOLD WASSER F: Dramatic recovery of paclitaxel-disabling neurosensory toxicity following treatment with venlafaxine. Anti-Cancer Drugs (2002) 13(7):777–780.
  • VENTAFRIDDA V, BONEZZI C, CARACENI A et al: Antidepressants for cancer pain and other painful syndromes with deafferentation component: comparison of amitriptyline and trazodone. ItaL J. NeuroL Sci. (1987) 8(6):579–587.
  • EHRNROOTH E, GRAU C, ZACHARIAE R, ANDERSEN J: Randomized trial of opioids versus tricyclic antidepressants for radiation-induced mucositis pain in head and neck cancer. Acta Oncol. (2001) 40(6):745–750.
  • ELPHICK MR, EGERTOVA M: The neurobiology and evolution of cannabinoid signalling. Philos. Trans. R. Soc. Lond. B. Biol. Sci. (2001) 356(1407):381–408.
  • SMITH FL, CICHEWICZ D, MARTIN ZL, WELCH SP: The enhancement of morphine antinociception in mice by delta9-tetrahydrocannabinol. PharmacoL Biochem. Behav. (1998) 60(2):559–566.
  • WELCH SP, FADS M: Synergistic interactions of endogenous opioids and cannabinoid systems. Brain Res. (1999) 848(1-2):183–190.
  • MENG ID, MANNING BH, MARTIN WJ, FIELDS HL: An analgesia circuit activated by cannabinoids. Nature (1998) 395(6700):381–383.
  • CAMPBELL FA, TRAMER MR, CARROLL D et al: Are cannabinoids an effective and safe treatment option in the management of pain? A qualitative systematic review. BMJ (2001) 323(7303):13–16.
  • STAATS PS, YEARWOOD T, CHARAPATA SG et al: Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial. /AMA (2004) 291(1):63–70.
  • DOGGRELL SA: Intrathecal ziconotide for refractory pain. Expert Opin. Investig. Drugs (2004) 13(7):875–877.
  • FERREIRA SH: The role of interleukins and nitric oxide in the mediation of inflammatory pain and its control by peripheral analgesics. Drugs (1993) 46(Suppl. 1):1–9.
  • SACHS D, CUNHA FQ, FERREIRA SH: Peripheral analgesic blockade of hypernociception: activation of arginine/NO/cGMP/protein kinase G/ATP-sensitive K+ channel pathway. Proc NatL Acad. Sci. USA (2004) 101(143680–3685.
  • VIVANCOS GG, PARADA CA, FERREIRA SH: Opposite nociceptive effects of the arginine/NO/cGMP pathway stimulation in dermal and subcutaneous tissues. Br. J. PharmacoL (2003) 138(7):1351–1357.
  • STICHTENOTH DO: The second generation of COX-2 inhibitors: clinical pharmacological point of view. Mini Rev. Med. Chem. (2004) 4(6):617–624.
  • FOX A, MEDHURST S, COURADE JP et al.: Anti-hyperalgesic activity of the COX-2 inhibitor lumiracoxib in a model of bone cancer pain in the rat. Pain (2004) 107(1-2):33–40.
  • FIORUCCI S, ANTONELLI E, BURGAUD JL, MORELLI A: Nitric oxide-releasing NSAIDs: a review of their current status. Drug Sal: (2001) 24(11):801–811.
  • YEH RK, CHEN J, WILLIAMS JL et al.: NO-donating nonsteroidal antiinflammatory drugs (NSAIDs) inhibit colon cancer cell growth more potently than traditional NSAIDs: a general pharmacological property? Biochem. PharmacoL (2004) 67(12):2197–2205.
  • JONZON B, BJARNASON I, HAWKEY G et al: The CINOD, AZD3582, exhibits an improved gastrointestinal safety profile compared with naproxen in healthy volunteers. Inflammopharmacology (2003) 11(4):437–444.
  • HOOGSTRAATE J, ANDERSSON LI, BERGE OG, JONZON B, OJTEG G: COX-inhibiting nitric oxide donators (CINODs) - a new paradigm in the treatment of pain and inflammation. Inflammopharmacology (2003) 11(4):423–428.
  • WENK GL, ROSI S, MCGANN K, HAUSS-WEGRZYNIAK B: A nitric oxide-donating flurbiprofen derivative reduces neuroinflammation without interacting with galantamine in the rat. Eur. J. PharmacoL (2002) 453(2-3):319–324.
  • VANBEVER R, LANGERS G, MONTMAYEUR S, PREAT V: Transdermal delivery of fentanyl: rapid onset of analgesia using skin electroporation. J. Controlled Release (1998) 50(1–3):225-235.
  • STRIEBEL HW, OLMANN T, SPIES C, BRUMMER G: Patient-controlled intranasal analgesia (PCINA) for the management of postperative pain: a pilot study. J. Clin. Anestesia (1996) 8:5–8.
  • BEYSSAC E, TOUAREF F, MEYER M et al.: Bioavailability of morphine after administration of a new bioadhesive buccal tablet. Biopharm. Drug Dispos. (1998) 19(6):401–405.
  • TASKER RA, CONNELL BJ, ROSS SJ, ELSON CM: Development of an injectable sustained-release formulation of morphine: antinociceptive properties in rats. Lab. Anim. (1998) 32(3):270–275.
  • BES JC, TKACZUK J, CZECH KA et al.: One-year chromaffin cell allograft survival in cancer patients with chronic pain: morphological and functional evidence. Cell Transplant. (1998) 7(3):227–238.
  • BUCHSER E, GODDARD M, HEYD B et al.: Immunoisolated xenogenic chromaffin cell therapy for chronic pain. Initial clinical experience [published erratum appears in Anesthesiology 1997 Feb; 86(2):509]. Anesthesiology (1996) 85(5):1005–1012; discussion 1029A–1030A.
  • ROMBERG R, OLOFSEN E, SARTON E et al.: Pharmacokinetic-pharmacodynamic modeling of morphine-6-glucuronide-induced analgesia in healthy volunteers: absence of sex differences. Anesthesiology (2004) 100(1):120–133.
  • ROMBERG R, SARTON E, TEPPEMA L et al.: Comparison of morphine-6-glucuronide and morphine on respiratory depressant and antinociceptive responses in wild type and mu-opioid receptor deficient mice. Br. J. Anaesth. (2003) 91(6):862–870.
  • FADDA P, BARLOCCO D, TRONCI S, CIGNARELLA G, FRATTA W: Antinociceptive action of DBO 17 and DBO 11 in mice: two 3,8 diazabicyclo (3.2.1.) octane derivates with selective mu opioid receptor affinity. Naunyn Schmiedebergs Arch. PharmacoL (1997) 356(5):596–602.
  • BURKEY TH, EHLERT FJ, HOSOHATA Y et al.: The efficacy of delta-opioid receptor-selective drugs. Lift Sci. (1998) 62(17-101531–1536.
  • MARIE N, LANDEMORE G, DEBOUT C, JAUZAC P, ALLOUCHE S: Pharmacological characterization of AR-M1000390 at human delta opioid receptors. Life Sci. (2003) 73(13):1691–1704.
  • SHAPIRA M, KEREN O, GAFNI M, SARNE Y: Divers pathways mediate delta-opioid receptor down regulation within the same cell. Brain Res. MoL Brain Res. (2001) 96(1-2):142–150.
  • ZADINA JE, HACKLER L, GE LJ, KASTIN AJ: A potent and selective endogenous agonist for the mu-opiate receptor. Nature (1997) 386(6624):499–502.
  • TAYLOR F, DICKENSON A: Nociceptin/orphanin FQ. A new opioid, a new analgesic? Neuroreport (1998) 9(12):R65–R70.
  • ZAVERI N: Peptide and nonpeptide ligands for the nociceptin/orphanin FQ receptor ORLI: research tools and potential therapeutic agents. Life Sci. (2003) 73(6):663–678.
  • MORK H, HOMMEL K, UDDMAN R, EDVINSSON L, JENSEN R: Does nociceptin play a role in pain disorders in man? Peptides (2002) 23(9):1581–1587.
  • MEUNIER JC: Nociceptin/orphanin FQ and the opioid receptor-like ORLI receptor. Eur. J. PharmacoL (1997) 340(1):1–15.
  • JUDD AK, KAUSHANSKAYA A, TUTTLE DJ et al.: N-terminal modifications leading to peptide ORLI partial agonists and antagonists. Pept. Res. (2003) 62(5):191–198.
  • YAMADA H, NAKAMOTO H, SUZUKI Y, ITO T, AISAKA K: Pharmacological profiles of a novel opioid receptor-likel (ORL(1)) receptor antagonist, JTC-801. Br. J. PharmacoL (2002) 135(2):323–332.
  • PARSONS CG, DANYSZ W, QUACK G: Memantine and the amino-alkyl-cyclohexane MRZ 2/579 are moderate affinity uncompetitive NMDA receptor antagonists-in vitro characterisation. Amino Acids (2000) 19(1):157–166.
  • BOYCE S, WYATT A, WEBB JK et al.: Selective NMDA NR2B antagonists induce antinociception without motor dysfunction: correlation with restricted localisation of NR2B subunit in dorsal horn. Neuropharmacdogy (1999) 38(5):611–623.
  • CHAZOT PL: The NMDA receptor NR2B subunit: a valid therapeutic target for multiple CNS pathologies. Curr. Med. Chem. (2004) 11(3):389–396.
  • SMITH PF: Therapeutic N-methyl-D-aspartate receptor antagonists: will reality meet expectation? Curr. Opin. Investig. Drugs (2003) 4(7):826–832.
  • STAHL SM: Anticonvulsants and the relief of chronic pain: pregabalin and gabapentin as alpha(2)delta ligands at voltage-gated calcium channels. J. Clin. Psychiatry (2004) 65(5):596–597.
  • SABATOWSKI R, GALVEZ R, CHERRY DA et al.: Pregabalin reduces pain and improves sleep and mood disturbances in patients with post-herpetic neuralgia: results of a randomised, placebo-controlled clinical trial. Pain (2004) 109(1-2):26–35.
  • MCCLEANE G, KOCH B, RAUSCHKOLB C: Does SPM 927 have an analgesic effect in human neuropathic pain? An open label study. Neurosci. Lett. (2003) 352(2):117–120.
  • DOST R, ROSTOCK A, RUNDFELDT C: The anti-hyperalgesic activity of retigabine is mediated by KCNQ potassium channel activation. Naunyn Schmiedebergs Arch. Pharmacol (2004) 369(4):382–390.
  • KAMINSKI RM, LIVINGOOD MR, ROGAWSKI MA: Allopregnanolone analogs that positively modulate GABA receptors protect against partial seizures induced by 6-Hz electrical stimulation in mice. Epi/epsia (2004) 45(7):864–867.
  • SHIN SW, EISENACH JC: Peripheral nerve injury sensitizes the response to visceral distension but not its inhibition by the antidepressant milnacipran. Anesthesiology (2004) 100(3):671–675.
  • LEO RJ, BARKIN RL: Antidepressant use in chronic pain management: is there evidence of a role for duloxetine? Prim. Care Companion J. Clin. Psychiatry (2003) 5(3):118–123.
  • FOX A, KESINGLAND A, GENTRY C et al: The role of central and peripheral Cannabinoidl receptors in the antihyperalgesic activity of cannabinoids in a model of neuropathic pain. Pain (2001) 92(1-2):91–100.
  • GUHRING H, SCHUSTER J, HAMZA M et al: HU-210 shows higher efficacy and potency than morphine after intrathecal administration in the mouse formalin test. Eur. J. Pharmacol. (2001) 429(1-3):127–134.
  • BRIDGES D, AHMAD K, RICE AS: The synthetic cannabinoid WIN55,212-2 attenuates hyperalgesia and allodynia in a rat model of neuropathic pain. Br. J. Pharmacol (2001) 133(4):586–594.
  • VALIVETI S, KIPTOO PK, HAMMELL DC, STINCHCOMB AL: Transdermal permeation of WIN 55,212-2 and CP 55,940 in human skin in vitro. Int. J. Pharm. (2004) 278(1):173–180.
  • ZHAN J, CHEN X, WANG C et el.: A fusion protein of conotoxin MVIIA and thioredoxin expressed in Escherichia coli has significant analgesic activity. Biochem. Biophys. Res. Commun. (2003) 311(2):495–500.
  • Does frog toxin represent a giant leap for treatment of pain? [news]. Gastroenterology (1998) 114(3):430. 132. WUHAO JX, ONGINI E et al.: Anitric oxide (NO)-releasing derivative of gabapentin, NCX 8001, alleviates neuropathic pain-like behavior after spinal cord and peripheral nerve injury. Br. J. Pharmacol. (2004) 141(1):65–74.
  • ROMERO-SANDOVAL EA, MAZARIO J, HOWAT D, HERRERO JF: NCX-701 (nitroparacetamol) is an effective antinociceptive agent in rat withdrawal reflexes and wind-up. Br. J. Pharmacol (2002) 135(6):1556–1562.
  • MOORE PK, MARSHALL M: Nitric oxide releasing acetaminophen (nitroacetaminophen). Dig. Liver Dis. (2003) 35\(Suppl. 2):549–560.
  • BERGER V, ALLOUI A, KEMENY JL et al: Evidence for a role for bulbospinal pathways in the spinal antinociceptive effect of systemically administered vapreotide in normal rats. Fundam. Clin. Pharmacol (1998) 12(2):200–204.
  • DECKER MW, MEYER MD: Therapeutic potential of neuronal nicotinic acetylcholine receptor agonists as novel analgesics. Biochem. Pharmacol (1999) 58(61:917–923.
  • PEUCKMANN V STRUMPF M, ZENZ M, BRUERA E: [Novel potential uses of thalidomide in the management of pain? A review of the literature]. Schmerz (2003) 17(3):204–210.
  • SZALLASI A: Vanilloid receptor ligands: hopes and realities for the future. Drugs Aging (2001) 18(8):561–573.
  • ROBBINS WR, STAATS PS, LEVINE J et al: Treatment of intractable pain with topical large-dose capsaicin: preliminary report. Anesth. Analg. (1998) 86(3):579–583.
  • PAIGE JA, FERRANS CE, LASHLEY FR et al: Topical capsaicin in the management of HIV-associated peripheral neuropathy. Pain Symptom Manage. (2000) 19(1):45–52.
  • MCEWAN AJ: Use of radionuclides for the palliation of bone metastases. Semin. Radiat. Oncol (2000) 10(2):103–114.
  • DAFERMOU A, COLAMUSSI P, GIGANTI M et al: A multicentre observational study of radionuclide therapy in patients with painful bone metastases of prostate cancer. Eur. j Nud Med. (2001) 28(7):788–798.
  • SARTOR O, REID RH, HOSKIN PJ et al: Samarium-153-lexidronam complex for treatment of painful bone metastases in hormone-refractory prostate cancer. Urology (2004) 63(5):940–945.
  • LIEPE K, KROPP J, RUNGE R, KOTZERKE J: Therapeutic efficiency of rhenium-188-HEDP in human prostate cancer skeletal metastases. Br. J. Cancer (2003) 89(4):625–629.
  • WINDSOR PM: Predictors of response to strontium-89 (Metastron) in skeletal metastases from prostate cancer: report of a single centre's 10-year experience. Clin. Oncol. (R Coll Radiol) (2001) 13(3):219–227.
  • PATRIGNANI P, CAPONE ML, TACCONELLI S: Clinical pharmacology of etoricoxib: a novel selective COX2 inhibitor. Expert Opin. Pharmacother. (2003) 4(2):265–284.
  • KELLSTEIN D, OTT D, JAYAWARDENE S, FRICKE J: Analgesic efficacy of a single dose of lumiracoxib compared with rofecoxib, celecoxib and placebo in the treatment of post-operative dental pain. Int. J. Clin. Pract. (2004) 58(3):244–250.
  • KEEBLE JE, MOORE PK: Pharmacology and potential therapeutic applications of nitric oxide-releasing non-steroidal anti-inflammatory and related nitric oxide-donating drugs. Br. J. Pharmacol (2002) 137(3):295–310.
  • HOUGHTON AK, PARSONS CG, HEADLEY PM: Mrz 2/579, a fast kinetic NMDA channel blocker, reduces the development of morphine tolerance in awake rats. Pain (2001) 91(3):201–207.
  • LUTFY K, DOAN P, WEBER E: ACEA-1328, a NMDA receptor/glycine site antagonist, acutely potentiates antinociception and chronically attenuates tolerance induced by morphine. Pharmacol Res. (1999) 40(5):435–442.
  • WALTERS MR, BRADFORD AP, FISCHER J, LEES KR: Early clinical experience with the novel NMDA receptor antagonist CNS 5161. Br. J. Clin. Pharmacol. (2002) 53(3):305–311.
  • DE VRY J, KUHL E, FRANKEN-KUNKEL P, ECKEL G: Pharmacological characterization of the chronic constriction injury model of neuropathic pain. Eur. J. Pharmacol. (2004) 491(2-3):137–148.
  • TOYOFUKU A, MIYAKO H: A case of temporo-mandibular disorder with fibromyalgia treated with the antidepressant, milnacipran. Hum. Psychopharmacol. (2004) 19(5):357–358.
  • DAJANI EZ, LARSEN KR, TAYLOR J et al.: 1,1-Dimethylheptyl-delta-8-tetrahydrocannabino1-11-oic acid: a novel, orally effective cannabinoid with analgesic and anti-inflammatory properties. Pharmacol. Exp. Ther. (1999) 291(1):31–38.
  • SCOTT DA, WRIGHT CE, ANGUS JA: Actions of intrathecal omega-conotoxins CVID, GVIA, MVIIA, and morphine in acute and neuropathic pain in the rat. Eur. J. Pharmacol. (2002) 451(3):279–286.
  • DM Q, LIU F, ZHOU Y et el.: The synthesis of SO-3, a conopeptide with high analgesic activity derived from Conus striatus. J. Nat. Prod. (2003) 66(9):1276–1279.
  • DI NAPOLI M, PAPA F: NCX-4016 Nic0x. Curr. Opin. Investig. Drugs (2003) 4(9):1126–1139.
  • MARIOTTO S, CUZZOLIN L, ADAMI A et al.: Effect of a new non-steroidal anti-inflammatory drug, nitroflurbiprofen, on the expression of inducible nitric oxide synthase in rat neutrophils. Br. J. Pharmacol. (1995) 115(2):225–226.
  • ROSSONI G, MANFREDI B, DEL SOLDATO P, BERTI F: The nitric oxide-releasing naproxen derivative displays cardioprotection in perfitsed rabbit heart submitted to ischemia-reperfitsion. J. Pharmacol. Exp. Ther. (2004) 310(2):555–562.
  • WORLD HEALTH ORGANIZATION: Cancer pain relief with a guide to opioid availability. (ed.) World Health Organization, Genf, (1996).

Websites

  • http//:www.who.int/entity/whr/ 192004/annex/topic/en/annex_2_en.pdf Deaths by cause, sex and mortality stratum in WHO regions, estimates for 2002 (2004).
  • httpll:www.cancer.org/downloads/STT/CAF F_finalPWSecured.pdf Cancer facts and figures 2004 (2004).
  • http//:www.who.int/cancer/media/en/788.pd f Global action against cancer (2004).
  • http//:www.clinicaltrials.gov Clinical Trials (2004).
  • http//:www.incb.org/e/tr/nar/ 192003/index.ht m Narcotic drugs (2003).
  • http//:www.wextech.ca/news/2003 /031101_ news.htm Phase II-a interim analysis on tectin for severe cancer related pain (2003).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.